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COMPARATIVE SAFETY AND EFFECTIVENESS OF CATHETER ABLATION VERSUS 
SURGERY FOR NEWLY DIAGNOSED ATRIAL FIBRILLATION  
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1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea, 2Seoul 
National University College of Medicine, Seoul, South Korea, 3Yonsei University College of 
Medicine, Seoul, South Korea  
OBJECTIVES: To assess comparative safety and effectiveness of catheter ablation 
(CA) versus surgery in patients with newly diagnosed atrial fibrillation(AF). 
METHODS: We used the national health claim database managed by Health 
Insurance Review and Assessment Service (HIRA) from 2007 to 2011. Patients 
with AF who aged 18-99 were identified using the I48* ICD-10 code. The eligible 
cohort was identified patients who diagnosed new AF in 2008 and treated with 
CA or surgery within 1 year of initial diagnosis. According to modality, 
characteristics of patient were analyzed. Patients were followed until in hospital 
death or December 31, 2011. Mortality and retreatment were analyzed by Cox-
proportion hazard regression. RESULTS: A total of 343 eligible patients with AF 
were composed of 220(82.7%) treated with CA, 123(15.8%) treated with surgery. 
Among treated patients, CHA2DS2 Score were 3.17±1.61 in CA and 4.13±1.67 in 
surgery. Mortality for patients treated with CA and surgery were 0.9% and 10.6% 
respectively, also retreatment rate were 50.9% and 15.4% respectively. Treatment 
modality was associated with retreatment rate of AF[adjusted hazard ratio(HR), 
0.33; 95% confidence interval (CI), 0.18-0.60] and no significant difference in 
mortality. The most common complication was heart failure. CONCLUSIONS: In 
this study, we found that mortality was higher treated with surgery than 
catheter ablation, but there was no significant difference and surgery is 
significantly superior in terms of retreatment rate. However, patients receiving 
catheter ablation therapy are more likely to be at low risk of stroke and follow-up 
time was not enough to compare mortality and complication incidence. 
Therefore, we need additional long-term studies using clinical data of AF.  
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OBJECTIVES: Atrial Fibrillation (AF) is the most common arrhythmia associated 
with a variety of cardiovascular conditions and increased rates of stroke, death. 
The aim of this study was to critically evaluate the current evidence on the use 
of radiofrequency catheter ablation (RFCA) for rhythm control compared with 
antiarrhythmic drug (AAD) therapy in patients with AF. METHODS: We searched 
potentially relevant studies using electronic databases such as Ovid-Medline, 
Ovid-EMBASE, Cochrane library, and seven Korean medical databases through 
May 2012. Two independent reviewers extracted data from each study using a 
standardized form. Disagreements between reviewers were resolved by 
discussion or in consultation with a third reviewer. The quality of the selected 
studies was assessed using the Cochrane risk of bias for randomized controlled 
trials (RCTs). A random-effects model was used to combine trials and the 
dichotomous data were presented as relative risk (RR) with 95% confidence 
intervals (CI). RESULTS: A total of 10 studies (8 RCTs) representing 930 patients 
were included. Their methodological quality was mostly poor. RFCA, in 
comparison with AAD therapy, significantly increased freedom from atrial 
tachycardia/AF (RR 3.06, 95% CI 2.34-3.99, P<0.00001, I2=55%) in 8 RCTs at one year 
follow-up. There was no difference in all-cause mortality (4 RCTs, RR 0.76, 95% CI 
0.18-3.19, P=0.71, I2=0%). Also, the rates of stroke/transient ischemic attack 
between both groups was insignificant (RR 1.95, 95% CI 0.34-11.04, P=0.83, I2=0%). 
Fewer complications were reported in the RFCA group compared with AAD group 
(RR 0.68, 95% CI 0.37-1.23, I2=45%). CONCLUSIONS: There is limited evidence to 
suggest that RFCA may be a better rhythm control treatment option compared  
to AAD therapy in patient with AF. Further rigorous RCTs with long-term  




LDL-C LEVEL AND GOAL ATTAINMENT AMONG PATIENTS WHO SWITCH FROM 
HIGHER-EFFICACY LIPID LOWERING THERAPIES TO SIMVASTATIN  
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OBJECTIVES: Elevated low-density lipoprotein cholesterol (LDL-C) is an 
influential risk factor for cardiovascular disease (CVD) morbidity/mortality. Our 
objective was to evaluate the impact of switches from higher-efficacy lipid-
lowering therapy (HELLT) to simvastatin on LDL-C levels and LDL-C goal 
attainment among high risk patients in UK. METHODS: This retrospective cohort 
study included individuals who received more than 2 months prescription of the 
following HELLT between 8/1/04 and 12/31/08: ezetimibe/simvastatin fixed dose 
combination (E/S), ezetimibe and simvastatin co-administration (E+S), ezetimibe 
and atorvastatin co-administration (E+A), ezetimibe and rosuvastatin co-
administration (E+R), rosuvastatin monotherapy and atorvastatin monotherapy. 
For each baseline HELLT, we used the analysis of covariance to estimate the least 
square mean difference in the percent change from baseline LDL-C between 
switchers and non-switchers, and logistic regression to estimate the odds ratio 
of LDL-C goal attainment (<3mmol/L for primary prevention and <2mmol/L for 
secondary prevention) at follow-up. RESULTS: A totoal of 30,148 patients from 
Clinical Practice Research Datalink met inclusion/exclusion criteria. E+A and E+R 
were excluded due to small number of switchers. 89.1% of switchers in 
atorvastatin group switched to an equivalent or higher efficacy dose of 
simvastatin, while 100% switching from E/S or E+S and 96.8% switching from 
rosuvastatin switched to lower than equivalent efficacy dose. The adjusted least 
squares mean difference of the percent change in LDL-C levels from baseline 
were 18.74% (95% confidence interval 8.6-28.9), 16.7% (12.8-20.6) and -0.1% (-1.8-
1.6) when switching from E/S or E+S, rosuvastatin and atorvastatin respectively 
compared to non-switchers. The odds of LDL-C goal attainment at follow-up for 
E/S or E+S, rosuvastatin and atorvastatin switchers were respectively 0.40 (0.23-
0.70), 0.36 (0.26-0.51) and 1.03 (0.92-1.15) relative to non-switchers. 
CONCLUSIONS: Among the high risk CVD population in the UK, switching to 
simvastatin from higher-efficacy lipid lowering therapy, especially rosuvastatin 
and simvastatin/ezetimibe FDC or co-administration results in higher LDL-C 
level and lower goal attainment rate.  
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OBJECTIVES: To compare cost-effectiveness of two metformin formulations 
(immediate release [IR] and extended release [XR]) in the cohort of patients with 
diabetes mellitus type-2 (DM2) and ischemic heart disease (IHD). METHODS: 
Cost-effectiveness analysis of metformin IR (Siofor® 500 mg tid) and metformin 
XR (Glucophage® Long 750 mg bid) was performed using cohort modeling. Daily 
dosage of metformin was the same for both formulations, 1500 mg a day. For a 
model cohort of 100 patients, annual cost of metformin treatment was 359,270 
RUB (11,841 USD) for metformin IR and 498,347 RUB (16,425 USD) for metformin 
XR. Effectiveness of the treatment was evaluated using the data of UKPDS  
study (1998), which demonstrated that 1% reduction of HbA1c led to 14% 
reduction of angina attacks rate. RESULTS: Assuming linear character of 
relationships between HbA1c level and angina attacks rate, and taking into 
account the data of Donnelly L.A. et al. (2008) that using metformin XR provides 
additional 0.7% reduction of HbA1c level, we suggested that administration of 
metformin XR would reduce the frequency of angina attacks in DM2 patients 
with OHD by 9.8%. It was assumed that average frequency of angina attacks  
in this cohort was 1 per year per patient; therefore administration of metformin 
XR instead of metformin IR would annually prevent approximately 10 cases  
of angina in the modeled cohort of 100 patients. According to standards of  
IHD treatment in Russia, angina attack treatment costs 19,970 RUB per patients 
(658 USD), for 10 patients it will total 199,700 RUB (6,580 USD). This sum might  
be saved by administration of metformin XR, and even taking into account 
higher cost of metformin XR, annual saving per 100 patients would be 60,600  
RUB per year (1,997 USD). CONCLUSIONS: Administration of metformin XR to 
patients with DM2 and IHD is more cost-effective that administration of 
metformin IR.  
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OBJECTIVES: Chronic Heart failure (CHF) is associated with significant morbidity 
and mortality. Angiotensin receptor blockers (ARBs) are one of most commonly 
prescribed drug class for patients with CHF among patients who are intolerant to 
angiotensin converting enzyme inhibitors (ACEI). A recently published Cochrane 
review concluded that ARBs as a class confer no additional benefit on mortality 
or total hospitalization as compared to placebo or ACEI. The aim is to compare 
efficacy of ARBs (losartan, valsartan, candesartan, and telmisartan) on 
hospitalization and mortality relative to each other and to placebo among 
patients with CHF. METHODS: Studies on ARBs were identified from a recently 
published Cochrane systematic review. A network meta-analysis (NMA) was 
conducted for three outcomes; all-cause hospitalizations, hospitalization due to 
heart failure, and all-cause mortality using WinBUGs. Binomial likelihood models 
were run for each outcome and analyses were conducted on an odds ratio scale. 
Fixed or random effects models were run to estimate relative treatment effects 
RESULTS: Sixteen studies were identified from the review. Five studies reported 
data on all-cause hospitalization and six on hospitalizations due to heart failure, 
for two drugs (candesartan and losartan).Data on mortality was reported in 16 
studies for losartan, valsartan, candesartan, and telmisartan. ARBs did not have 
significantly different effects from placebo or each other on all the three 
outcomes studied. NMA can also be used to rank treatments. Within this we 
found that compared to all other ARBs, telmisartan and losartan had the highest 
probabilities of being the best treatments to reduce mortality and 
hospitalizations, respectively. CONCLUSIONS: Results of the NMA indicated that 
there was no significant difference between any of the individual ARBs, ACEI or 
placebo on mortality and hospitalization. A further analysis that uses meta-
regression to adjust for co-morbid conditions such as diabetes, hypertension and 
ischemic heart disease is warranted.  
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OBJECTIVES: To describe methods used and successes realized in building the 
infrastructure to conduct pragmatic clinical trials of comparative effectiveness 
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research (CER) in Washington State’s Learning Healthcare System - the 
Comparative Effectiveness Research Translation Network (CERTAIN). METHODS: 
Leveraging the infrastructure of the Surgical Care and Outcomes Assessment 
Program (SCOAP), a statewide coordinated quality improvement program that 
tracks surgical outcomes in hospitals, we created an infrastructure for 
conducting CER/PCOR. We are using the CERTAIN network to conduct a 
pragmatic clinical trial – a multi-site, prospective, observational cohort study of 
patients in community settings with peripheral artery disease (PAD) treated with 
open surgical, endovascular, or conservatively managed care. Clinical and 
patient-reported outcomes (PRO) are collected at baseline, 30-days, 6- and 12-
months post intervention. The primary outcome is the change in scores on the 
Walking Impairment Questionnaire. The SCOAP Medical Director engaged PAD-
treating vascular surgeons, interventional radiologists and cardiologists. Study 
staff educated all institutional review boards about pragmatic trials. The SCOAP 
CERTAIN Survey Center administers all PRO surveys using a mode of 
administration of each patient’s choice (e.g. web-based, paper-pencil); and 
deploys vigorous follow-up contact algorithms to retain patients. RESULTS: Over 
18-months, 15 sites have been engaged and are enrolling patients. Over 5500 
medical records have been screened; 1016 patients (18%) with PAD identified. 
415/1,016 (41%) met all inclusion criteria and received enrollment packets, 193 
are actively participating, 14 have completed the study. Enrollment continues 
through September 2013. In companion work, CERTAIN Investigators developed 
their own ‘symptom’ instrument, informed by interviews with 11 patients; and 
are conducting a sub-study to compare scores on PRO instruments administered 
using various modes of administration. CONCLUSIONS: This CERTAIN PAD study 
illustrates the effort required to conduct a pragmatic trial. As the nation 
embraces the research paradigm of CER, Washington State’s Learning Healthcare 
System is modeling success.  
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OBJECTIVES: Heart failure (HF) is associated with increased risk of dementia and 
dementia is an independent predictor of hospitalization in HF patients. Studies 
show dyslipidemia may be involved in the pathogenesis of dementia. However, it 
is unclear whether statins are associated with risk of dementia in HF patients. 
The present study examines the effectiveness of statins to prevent dementia in 
HF patients. METHODS: This retrospective, longitudinal study used a cohort of 
patients with HF identified from a local Medicare advantage prescription drug 
plan to examine incidence of dementia with up to 3 years of follow up period. 
Multivariable time dependent Cox model and inverse-probability-of-treatment 
weighting (IPTW) of marginal structural model were used to estimate the risk of 
developing dementia controlling for sociodemographic factors, comorbidities, 
comedications, appropriate laboratory measures, and potential time-varying 
confounding affected by previous treatment (hospitalization and low density 
lipoprotein test). Adjusted dementia rate ratios were estimated among current 
and former statin users, as compared with nonusers. RESULTS: The study 
included a total of 8062 HF patients (mean age 74.47±9.21 years) of which 1135 
(14.08 %) patients were diagnosed with dementia during the median follow up of 
22 months. Using the time dependent Cox model, the adjusted dementia rate 
ratios (95% confidence interval) among current and former users were 0.93 (0.71-
1.21) and 0.99 (0.79-1.25). Use of IPTW resulted in similar findings with rate ratios 
(95% conservative confidence interval) of 1.24 (0.89-1.72) among current users 
and 0.94 (0.67-1.31) for former users as compared with the nonusers. 
CONCLUSIONS: This study found no difference in risk of dementia among the 
current and former users of statin as compared with the nonusers in an already 
at-risk HF population.  
 
PCV27  
EXAMINING THE RATE OF MYOCARDIAL INFARCTION AND ASSOCIATED 
COSTS IN PATIENTS CONCOMITANTLY RECEIVING CLOPIDOGREL AND 
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OBJECTIVES: The purpose of this study was to examine the rate of myocardial 
infarctions (MI) and associated event costs in patients prescribed clopidogrel and 
a concomitant PPI. METHODS: This was a retrospective study of administrative 
claims using the IMS Lifelink Database. Adult GERD patients concomitantly 
prescribed clopidogrel and PPI ≥ 30 days from July 1, 2005-December 31, 2009 
were identified. Patients were required to have continuous insurance coverage 
for ≥ 6 months prior to the concomitant therapy start date. Patients were 
followed until a MI (based upon emergency department or inpatient 
hospitalization diagnosis), medication discontinuation, loss of insurance 
coverage, or one year, whichever occurred first. RESULTS: A total of 64,370 
PPI+clopidogrel patients (40.3% female) were identified. Of these, 17,260 (26.8%) 
were prescribed esomeprazole, 7,237 (11.2%) received lansoprazole, 24,510 (38.1%) 
received omeprazole, 13,373 (20.8%) received pantoprazole, and 1,990 (3.1%) 
received rabeprazole. Rates of MI in these patients ranged from 3.1% (4.74 per 100 
person years) for rabeprazole to 6.3% (10.31 per 100 person years) for 
pantoprazole. Cox proportional hazards model controlling for gender, age, 
Charlson comorbidity index score, and cardiovascular comorbid conditions at 
baseline, showed the risk of MI was significantly lower for rabeprazole (adjusted 
hazard ratio [HR]=0.753; P=0.0315), lansoprazole (HR=0.870; P=0.0373), and 
esomeprazole (HR=0.893; P=0.0203) when compared to omeprazole, while higher 
for pantoprazole (HR=1.197; P=0.0001). The average MI hospitalization event cost 
for patients with an event was $31,806, and the average MI-related emergency 
department visit cost was $1,934. CONCLUSIONS: The rate of MI was different 
among PPIs when used in combination with clopidogrel. These differences in MI 
rates may have important clinical implications as well as a significant economic 
impact given the high cost of MI-related hospitalizations and emergency 
department visits. Further studies are needed to evaluate the differences 
between these cohorts.  
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OBJECTIVES: Discontinuation rates for vitamin K antagonists (VKAs) are high in 
patients with atrial fibrillation (AF). The aim of the current study was to assess 
the impact of VKA persistence compared to that of rivaroxaban, a new oral 
anticoagulant (NOAC) taken once daily and requiring no monitoring, on the 
incidence of ischemic strokes in patients with AF. METHODS: Data relating to 
persistence rates of warfarin and rivaroxaban over 18 months of patient follow-
up was derived from the literature. A model was developed synthesising these 
data with published ischaemic stroke rates and the effect of switching to an 
alternative treatment. The model assumed an annual risk of ischaemic stroke of 
1.65% and 5.00% for patients receiving warfarin or no treatment, respectively. To 
obtain the risk of stroke for patients receiving rivaroxaban, a relative risk of 0.94 
was applied to the warfarin risk giving an annual probability of 1.55%. 
Publications suggest that persistence after 180 days is 44% for warfarin and 78% 
for rivaroxaban. Sensitivity analyses on persistence rates of rivaroxaban were 
conducted to account for uncertainty. RESULTS: Patients starting treatment with 
a VKA stayed on treatment for an average of 226 days. In contrast, patients 
starting on rivaroxaban stayed on treatment for approximately 412 days. The 
total ischaemic stroke risk at 18 months was estimated to be 5.15% and 3.48–
4.07% for patients initiating therapy with warfarin or rivaroxaban, respectively. 
For a hypothetical cohort of 10,000 patients with AF the sensitivity analyses 
showed that the greater persistence with rivaroxaban would translate to 108–167 
strokes avoided. CONCLUSIONS: Our model indicates that starting patients on 
rivaroxaban may decrease the number of total ischaemic strokes relative to 
warfarin treatment. Moreover, this decrease may correspondingly reduce the 
burden of stroke-related costs borne by health care systems.  
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OBJECTIVES: To determine the pattern and predictors of use of acute 
pharmacological treatment (anti-platelet agents and beta-blockers) given in the 
emergency department (ED) to older adults with acute myocardial infarction 
(AMI). METHODS: Data from the National Hospital Ambulatory Medical Care 
Survey (NHAMCS) ED component from years 1992 to 2010 were used for the 
cross-sectional study. Patients were included if they had an admission diagnosis 
of AMI (ICD-9-CM code 410.xx) and were ≥55 years. Drug users were divided into 
4 groups: anti-platelet agents only, beta-blockers only, anti-platelet agents & 
beta-blockers, and non-users. Survey logistic regression was used to examine the 
trend in the use of drugs across the years and whether age predicted drug use. 
All the visits were weighted to obtain national estimates. All the analysis were 
carried out in SAS 9.3. RESULTS: A total of 1771 visit (weighted: 6.1 million visits) 
by patients were selected for this study. Almost 54% [95% CI: 51.7% to 57.1%] of 
our population are females with a mean age of 72 (SE=0.33) years. This 
population is 87% white [95% CI: 84.9% to 89.1%] and 94% non-Hispanic [95% CI: 
91.8% to 95.3%]. Both anti-platelet agents and beta-blockers showed to have a 
positive trend across the years (OR=1.09 [95% CI: 1.07 to 1.19] and OR=1.16 [95% 
CI: 1.13 to 1.19], respectively). Age was a significant predictor of anti-platelet 
agents use (OR=0.76 [95% CI: 0.62 to 0.93]), older adults (≥65) were less likely to 
receive an anti-platelet agent than younger adults; however, age was not 
considered to be a significant predictor of beta-blocker use. CONCLUSIONS: This 
study displayed a positive pattern across the years in the use of acute 
pharmacological treatment given for older AMI patients. It also suggested that 
older adults were less likely to be treated acutely with anti-platelet agents.  
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QATAR (2007-2011)  
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OBJECTIVES: Cardiovascular diseases (CVDs) are the leading cause of 
death/disability in Qatar. Nonetheless, there are no any Qatari data that 
describes the patterns of using drugs for the CVD. This study sought to assess 
changes in the ‘utilization’ and ‘expenditures’ of cardiovascular drugs over time. 
METHODS: The study is conducted from the Hamad Medical Corporation (HMC) 
setting, whereby utilization and expenditures data were obtained from HMC 
drug databases that are based on the 2007- 2011 period. Data were categorized by 
drug, drug concentration, drug class, year, and hospital. Descriptive statistics 
were used to illustrate distributions of variables, and cross-tabulation was used 
to provide comparison of frequency data. RESULTS: An increasing trend in 
utilization and expenditures was associated with the use of cardiovascular 
drugs. The rise in expenditure was more substantial as compared to utilization 
